6955 — Shandong Boan Biotechnology Share News
0.000.00%
Last trade - 00:00- HK$1.96bn
- HK$1.66bn
- CNY784.82m
Brief: Shandong Boan Biotechnology Updates On Clinical Trials For Dulaglutide Injection In U.S.
Brief: Shandong Boan Biotechnology Says Total Shares Sold Under Placement 26.7 Mln Shares
Brief: Shandong Boan Biotechnology Says Approval For Initiating Clinical Trial For Novel ADC Candidate In China
Brief: Shandong Boan Biotechnology Sees Profit For Six Months Of No Less Than RMB60 Mln
Brief: Shandong Boan Biotechnology Says BLA For Aflibercept Intravitreous Injection Accepted In China
Brief: Shandong Boan Biotechnology Says Biologics License Application For Dulaglutide Injection Accepted By NMPA China
Brief: Shandong Boan Biotechnology Says Denosumab Injection (Boluojia) For Oncology Indications Approved For Marketing By NMPA
Brief: Shandong Boan Biotechnology Announces Loan Facility
Brief: Shandong Boan Biotechnology Announces FY Loss Attributable Of RMB119.4 Mln
Brief: Shandong Boan Biotechnology Says Planning To Submit Biologics License Application For Dulaglutide Injection, Ba5101
Brief: Shandong Boan Biotechnology Says Exclusive License Agreement For Ba2101
Brief: Shandong Boan Biotechnology Says Ba1105 And Ba1301 Granted Orphan Drug Designations By FDA
Brief: Shandong Boan Biotechnology Gets GMP Certification For Boyuno®
Brief: Shandong Boan Biotechnology Says Both BA1105 & BA1301 Being Granted Orphan Drug Designations By FDA
Brief: Shandong Boan Biotechnology Says BA1202 Approved For Clinical Trials By NMPA
Brief: Shandong Boan Biotechnology Completes Patient Enrollment in China For PhaseIII Study Of Ba5101
Brief: Shandong Boan Biotechnology Says Biologics License Application For Boyounuo Accepted In Brazil
Brief: Shandong Boan Biotechnology Reports FY Loss For Year Attributable RMB331.7 Mln
Shandong Boan Biotechnology hits record high on drug's commercialization hope